Challenges and Solutions for Integrating and Financing Personalized Medicine in Healthcare Systems: A Systematic Literature Review

被引:5
作者
Kalouguina, Veronika [1 ]
Wagner, Joel [1 ,2 ]
机构
[1] Univ Lausanne, Fac HEC, Dept Actuarial Sci, CH-1015 Lausanne, Switzerland
[2] Univ Lausanne, Swiss Finance Inst, CH-1015 Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
personalized medicine; health insurance; financial management; genetics; COVERAGE POLICY DEVELOPMENT; EVIDENCE GENERATION; PAYER COVERAGE; MARKET ACCESS; ORPHAN DRUGS; REIMBURSEMENT; PERSPECTIVES; BARRIERS; PHARMACOGENETICS; RECOMMENDATIONS;
D O I
10.3390/jrfm13110283
中图分类号
F8 [财政、金融];
学科分类号
0202 ;
摘要
The scope and ambitions of biomedical institutions worldwide currently working toward the integration of personalized medicine (PM) require recognizing the potential profound impact on regulatory standards and on the economic functioning and financing of healthcare. Against this background, researchers and policymakers must manage the arising challenges for the healthcare systems. In this paper we study the literature related to the consequences of PM on health insurance and care systems. Using the PRISMA research protocol, we search the existing body of literature and analyze publications dealing with insurance (419 papers) in the field of PM. After a detailed reading of the 52 studies included in our analysis, we synthesize challenges in three fields that must be addressed to avoid hindering the implantation of PM. The key issues that we highlight concern (1) a lack of clear and consistent data on the economic relevance of PM, (2) a value-oriented and cost-efficient definition of reimbursement thresholds, (3) the implementation of PM in the prevailing healthcare system. In the meantime, we provide several solutions to these concerns; we present (a) risk-sharing contracts that can deal with the emerging coverage challenges, (b) criteria that could constitute future reimbursement thresholds and (c) examples of successful implementations of PM into healthcare systems. Our findings are relevant for policymakers and health insurance companies for redefining the guidelines for the healthcare schemes of the future.
引用
收藏
页数:22
相关论文
共 64 条
[1]   Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine? [J].
Akhmetov, Ildar ;
Bubnov, Rostyslav V. .
EPMA JOURNAL, 2017, 8 (01) :5-15
[2]   Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests [J].
Amendola, Laura M. ;
Hart, M. Ragan ;
Bennett, Robin L. ;
Horike-Pyne, Martha ;
Dorschner, Michael ;
Shirts, Brian ;
Jarvik, Gail P. .
JOURNAL OF GENETIC COUNSELING, 2019, 28 (06) :1208-1213
[3]   The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments [J].
Antonanzas, Fernando ;
Juarez-Castello, Carmelo ;
Lorente, Reyes ;
Rodriguez-Ibeas, Roberto .
PHARMACOECONOMICS, 2019, 37 (12) :1469-1483
[5]   Governance of conditional reimbursement practices in the Netherlands [J].
Boon, Wouter ;
Martins, Luis ;
Koopmanschap, Marc .
HEALTH POLICY, 2015, 119 (02) :180-185
[6]   Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare [J].
Carrera, Pricivel ;
IJzerman, Maarten J. .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (04) :435-437
[7]   Pharmacogenetics and cost-effectiveness analysis: a two-way street [J].
Chalkidou, Kalipso ;
Rawlins, Sir Michael .
DRUG DISCOVERY TODAY, 2011, 16 (19-20) :873-877
[8]   Clinical and economic challenges facing pharmacogenomics [J].
Cohen, J. ;
Wilson, A. ;
Manzolillo, K. .
PHARMACOGENOMICS JOURNAL, 2013, 13 (04) :378-388
[9]   Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement [J].
Cohen, Joshua P. ;
Felix, Abigail E. .
JOURNAL OF PERSONALIZED MEDICINE, 2014, 4 (02) :163-175
[10]   A review of international coverage and pricing strategies for personalized medicine and orphan drugs [J].
Degtiar, Irina .
HEALTH POLICY, 2017, 121 (12) :1240-1248